Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PILOT-STUDY OF IMMUNOTHERAPY USING INTERLEUKIN-2 IN CHILDREN WITH SOLID TUMORS OR LYMPHOMAS
Autore:
BOUFFET E; MICHON J; FRAPPAZ D; NEGRIER S; COMBARET V; DELATTRE O; COCHAT P; FLORET D; DOZ F; STAMM D; CLAPISSON G; OSKAM R; LASSET C; PACQUEMENT H; ZUCKER JM; BRUNATMENTIGNY M; FAVROT M; PHILIP T;
Indirizzi:
CTR LEON BERARD,DEPT PEDIAT,28 RUE LAENNEC F-69373 LYON 8 FRANCE INST CURIE,DEPT PEDIAT ONCOL PARIS FRANCE HOP EDOUARD HERRIOT,PEDIAT INTENS CARE UNIT LYON FRANCE CHIRON CORP AMSTERDAM NETHERLANDS
Titolo Testata:
International journal of pediatric hematology/oncology
fascicolo: 6, volume: 2, anno: 1995,
pagine: 489 - 493
SICI:
1070-2903(1995)2:6<489:POIUII>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-CELL-CARCINOMA; RECOMBINANT INTERLEUKIN-2; KILLER-CELLS; PHASE-I; NEUROBLASTOMA; THERAPY; CANCER; MALIGNANCIES; INFUSION;
Keywords:
INTERLEUKIN 2 THERAPY; SOLID TUMORS; LYMPHOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
E. Bouffet et al., "PILOT-STUDY OF IMMUNOTHERAPY USING INTERLEUKIN-2 IN CHILDREN WITH SOLID TUMORS OR LYMPHOMAS", International journal of pediatric hematology/oncology, 2(6), 1995, pp. 489-493

Abstract

Purpose: A pilot study using recombinant interleukin 2 (rIL-2) was undertaken to assess the efficacy of this cytokine in children with advanced cancers. Patients and Methods: Twelve assessable patients enteredthe study. They were treated either by continuous infusion (four patients) or by bolus-type infusion (eight patients). Treatment consisted of one to two cycles of rIL-2, at a dose of 18 x 10(6) IU/m(2)/day (continuous infusion) or 18 x 10(6) IU/m(2)/8 hours (bolus schedule) for 5 days, followed by a 6-day rest. The same dose of rIL-2 was infused again for 4 1/2 days starting on day 12. Patients with no evidence of progression received an identical second course of treatment after a 3-week rest. Results: A minor response was achieved in one patient. All other patients had stable or progressive disease after one (nine patients) or two cycles (two patients). Toxicity was mainly renal and cardiovascular, leading to dose modifications in 10 of 12 patients. Conclusions: This phase I/II study shows that minimal antitumor activity is obtained by isolated rIL-2 treatment in end-stage disease. Based on experimental models, the authors suggest that the rIL-2 therapy may be effective only if instituted earlier in the course of the disease and/oris associated with alternative treatments.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 10:36:04